SCHEMBL755840

SCHEMBL755840

Cc1nc(N)cc(-c2c(Nc3cccc(NC(=O)Cc4ccccc4)c3)nc3ccccn23)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.54
MTOR P42345 6/20 0.54
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SIRT2 Q8IXJ6 1/20 0.45
MAPT P10636 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
LMNA P02545 2/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.40
AKT1 P31749 1/20 0.40
USP2 O75604 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11027619 0.88 PIK3CA (0.60) PIK3CAMTORSMN1; SMN2MAPTRAB9A
SCHEMBL751742 0.88 PIK3CA (0.52) PIK3CAMTORSMN1; SMN2NPC1RAB9A
SCHEMBL756108 0.87 PIK3CA (0.59) PIK3CAMTORALDH1A1KDM4ESMN1; SMN2
SCHEMBL756457 0.87 PIK3CA (0.56) PIK3CAMTORALDH1A1KDM4ESMN1; SMN2
SCHEMBL751149 0.86 PIK3CA (0.57) PIK3CAMTORSMN1; SMN2RAB9AKDR
SCHEMBL752472 0.85 PIK3CA (0.54) PIK3CAMTORKDM4ESMN1; SMN2RAB9A
SCHEMBL750596 0.83 PIK3CA (0.56) PIK3CAMTORKDM4ESMN1; SMN2KDR
SCHEMBL2790005 0.83 PIK3CA (0.62) PIK3CAMTORALDH1A1HPGDFLT1
SCHEMBL751735 0.82 PIK3CA (0.54) PIK3CAMTORALDH1A1KDM4EKDR
SCHEMBL750438 0.80 PIK3CA (0.57) PIK3CAMTORALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885ALDH1A1 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.